Serum levels of CA19-9 may be as an indicator for metastases in patients with non-small cell lung cancer.

Autor: Liu, Xing'an, Shan, Guoyong, Zhang, Song, Lei, Kaijian
Zdroj: Chinese-German Journal of Clinical Oncology; Dec2011, Vol. 10 Issue 12, p692-694, 3p
Abstrakt: Objective: The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer (NSCLC) and to analyze the relationship between serum levels of CA19-9 and metastasis. Methods: Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively. The relationship between serum levels of CA19-9 and sites of metastasis were analyzed. Results: Of the 1200 patients, 528 were stage IV and the positive rate of CA19-9 was 32% (169 cases) and 288 stage III, positive rate 20% (58 cases); 144 stage II, positive rate 12% (17 cases); 240 stage I, positive rate 3% (7 cases). There were statistical differences from stage I to stage IV ( P < 0.01). The total positive rate in the 1200 cases was 21%. Furthermore, of the 528 stage IV cases, 350 had bone metastasis and the positive rate of CA19-9 was 43% (150 cases) in bone metastatic cases. In turn, in CA19-9 positive patients (169 cases) of stage IV, the positive rate of bone metastasis was 89% (150/169). There was no statistical difference of positive rate of CA19-9 between adenocarcinoma and squamous carcinoma ( P > 0.05). Conclusion: Positive rate of CA19-9 increases accordingly from stage I to stage IV. The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC, especially for bone metastasis in stage IV diseases. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: